Percutaneous radiofrequency ablation for small hepatocellular carcinoma in hepatic dome under MR-guidance: clinical safety and efficacy

Chen, Jin; Lin, Zhong‐Zhe; Lin, Qingfeng; Lin, Ruixiang; Yuan, Yan; Chen, Jian

doi:10.1080/02656736.2020.1728397

Cited by 14 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CT-guided RFA is also limited for delineating the induced ablation zone. Guidance of RFA using magnetic resonance imaging (MRI) outperforms both these imaging modalities but has the drawback of increased treatment complexity and cost 12 , 13 .…”

Section: Introductionmentioning

confidence: 99%

Optical signatures of radiofrequency ablation in biological tissues

Lanka

Francis

Kruit

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Accurate monitoring of treatment is crucial in minimally-invasive radiofrequency ablation in oncology and cardiovascular disease. We investigated alterations in optical properties of ex-vivo bovine tissues of the liver, heart, muscle, and brain, undergoing the treatment. Time-domain diffuse optical spectroscopy was used, which enabled us to disentangle and quantify absorption and reduced scattering spectra. In addition to the well-known global (1) decrease in absorption, and (2) increase in reduced scattering, we uncovered new features based on sensitive detection of spectral changes. These absorption spectrum features are: (3) emergence of a peak around 840 nm, (4) redshift of the 760 nm deoxyhemoglobin peak, and (5) blueshift of the 970 nm water peak. Treatment temperatures above 100 °C led to (6) increased absorption at shorter wavelengths, and (7) further decrease in reduced scattering. This optical behavior provides new insights into tissue response to thermal treatment and sets the stage for optical monitoring of radiofrequency ablation.

show abstract

Section: Introductionmentioning

confidence: 99%

Optical signatures of radiofrequency ablation in biological tissues

Lanka

Francis

Kruit

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Many locoregional therapies for HCC, particularly small HCC (SHCC) therapies such as radiofrequency ablation (RFA), transcatheter arterial chemoembolization, and microwave coagulation ablation, have been developed. It is well documented that RFA is a safe and effective therapy for SHCC [ 5 , 6 ]. Chen et al recently reported that, in patients treated by RFA, progression-free survival time and 5-year survival rate are 25.0 ± 22.7 months (median: 17.0 months) and 28.5%, respectively [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…It is well documented that RFA is a safe and effective therapy for SHCC [ 5 , 6 ]. Chen et al recently reported that, in patients treated by RFA, progression-free survival time and 5-year survival rate are 25.0 ± 22.7 months (median: 17.0 months) and 28.5%, respectively [ 6 ]. However, the underlying mechanisms associated with the treatment by RFA are not fully understood.…”

Section: Introductionmentioning

confidence: 99%

Changes of immune cells in patients with hepatocellular carcinoma treated by radiofrequency ablation and hepatectomy, a pilot study

et al. 2021

Open Life Sciences

View full text Add to dashboard Cite

In this pilot study, we compared the dynamic changes of circulating immune cells between patients with hepatocellular carcinoma (HCC) who underwent radiofrequency ablation (RFA) and hepatectomy. Seventy-three patients were enrolled in this study. Flow cytometry assay was performed to determine the immune cells in the peripheral blood mononuclear cells (PBMCs) before treatment and on days 7, 14, and 28 after treatment. We found that in the RFA group, the circulating cluster of differentiation (CD)4+ cells, the CD4+/CD8+ ratio, and natural killer (NK) cells continued to increase, and the circulating CD8+ cells continued to decrease after the treatment. In contrast, in the surgery group, the circulating CD4+ cells and CD4+/CD8+ ratio decreased over the first seven postoperative days and then began to increase, and CD8+ cells decreased on the first 7 postoperative days and began to increase thereafter. The changes of immune cells in tumor tissues consisted of an increase in the number of CD4+ cells, CD8+ cells, CD3+ cells, and NK cells immediately after RFA. Our results show that postoperative immune function continued to improve after RFA, but after surgery, it decreased in the first week and started to improve thereafter. These findings are important for clinicians when selecting the appropriate therapy for HCC.

show abstract

“…Recently, MR-guided ablation has been gradually applied to the minimally invasive treatment of primary and metastatic renal malignancies [17,18]. The MR-guided method could ensure precise insertion of the applicator into the target tissue and enable monitoring and controlling the degree of tissue coagulation, to confirm that the tumor has been completely destroyed as well as reduce the impact on normal renal tissue and thermal damage to adjacent structures [19][20][21][22]. The characteristic of coagulative necrosis during MR-guided ablation is that the signal intensity on T2WI decreases while the signal intensity on T1WI increases.…”

Section: Discussionmentioning

confidence: 99%

MR-Guided Microwave Ablation in T1 Renal Cell Carcinoma: Initial Results in Clinical Routine

Jiao

Wang

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Objective. Percutaneous tumor ablation is usually performed using computed tomography (CT) or ultrasound (US) guidance, although reliable visualization of the target tumor could be challenging. Magnetic resonance- (MR-) guided ablation provides more reliable visualization of the target tumors and allows multiplanar imaging of the treatment process, making it the modality of choice, in particular if lesions are small. Methods. From March 2016 to January 2018, 32 patients scheduled for percutaneous treatment of T1 RCC underwent MR-guided MWA. Complications were classified according to the Clavien grade. Kaplan–Meier survival estimates were calculated to evaluate progression-free survival (PFS). Results. Technical success was achieved in all lesions. The mean energy and procedure duration were 61.6 ± 8.7 kJ and 118.2 ± 26.7 min, respectively. The glomerular filtration rate (GFR) dropped rapidly after 1 month of treatment and slowly recovered within three months ( P < 0.05 ). Postoperative pain and fever were the most common adverse events after treatment. Perirenal hematoma, thermal injury of the psoas muscle, and abdominal distension were common complications after MWA, and the incidence rates were 9.4% (3/32), 6.3% (2/32), and 6.3% (2/32), respectively. According to the Clavien grade classification, serious complications include hydrothorax, bowel injury, and renal failure, all of which have a probability of 3.1%. Of note, the three serious complications occurred in one patient. The 1-, 2-, and 3-year PFS rates were 96.9%, 93.8%, and 83.9%, respectively. The mean PFS rates were 33.972 months (95% CI: 33.045, 35.900). Conclusion. Microwave ablation is feasible under MR guidance and provides effective treatment of RCC in one session.

show abstract

Percutaneous radiofrequency ablation for small hepatocellular carcinoma in hepatic dome under MR-guidance: clinical safety and efficacy

Cited by 14 publications

References 27 publications

Optical signatures of radiofrequency ablation in biological tissues

Optical signatures of radiofrequency ablation in biological tissues

Changes of immune cells in patients with hepatocellular carcinoma treated by radiofrequency ablation and hepatectomy, a pilot study

MR-Guided Microwave Ablation in T1 Renal Cell Carcinoma: Initial Results in Clinical Routine

Contact Info

Product

Resources

About